Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
- Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome.
- The new CAB brings unparalleled expertise in basement membrane biology, genetic kidney diseases, and glomerular disorders, providing critical guidance as Fibrocor advances its first-in-class pipeline towards the clinic.
- These appointments mark a key milestone as Fibrocor accelerates development of its disease-modifying therapies for Alport Syndrome, a severe genetic kidney disease with no approved treatments and significant global unmet need.
Toronto, Canada / Leuven Belgium – 9 December 2025 Fibrocor Therapeutics Inc. (‘Fibrocor’ or ‘the Company’), a biotech company developing first-in-class therapies for kidney diseases, with a strong focus on Alport Syndrome, today announces the appointment of four internationally recognized authorities in nephrology and genetics to its newly formed Clinical Advisory Board (CAB), underscoring the company’s accelerating momentum and scientific leadership.
